Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001828 · ClinicalTrials.gov registry record · Phase 1
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia, Adult, sponsored by Polaris Group.
- Active
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 3
- Study locations
NCT05001828: Active Phase 1 study of Acute Myeloid Leukemia, Adult, sponsored by Polaris Group.
NCT05001828 is a Phase 1 study of Acute Myeloid Leukemia, Adult that is active but no longer recruiting, run by Polaris Group. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05001828, a Phase 1 study of Acute Myeloid Leukemia, Adult, is active but no longer recruiting, sponsored by Polaris Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.
Conditions Studied
Interventions
- DRUG ADI-PEG 20
Study Locations (3)
Florida
- Sylvester Comprehensive Cancer Center - Miami
North Carolina
- Levine Cancer Institute - Charlotte
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05001828 still lists
NCT05001828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Acute Myeloid Leukemia, Adult appearing as the primary indexed condition, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT05001828 reports a single indexed study location in Florida, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05001828 about?
NCT05001828 is a clinical study titled "Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia". Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be ad...
What is the current status of trial NCT05001828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-04-05. Estimated completion is 2026-12.
What conditions does trial NCT05001828 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Adult.
What interventions are being tested in trial NCT05001828?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT05001828?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05001828 being conducted?
This trial has 3 study locations across Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05001828's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI